Aneurysmal Subarachnoid Hemorrhage Market - Global Industry Trend Analysis 2012 to 2017 and Forecast 2017 - 2025


#11995

Persistence Market Research

$ 4900

?Aneurysmal subarachnoid hemorrhage is sudden bleeding into the subarachnoid space. It might spill into the cerebrospinal liquid in the space around the brain. The most widely recognized reason for unconstrained blood draining is a cracked aneurysm. Side effects may incorporate sudden and extreme cerebral pain. In more genuine cases, the bleeding may cause total brain damage with loss of motion or coma. In the most serious cases, the draining may lead to severe death of an individual. It is an overall wellbeing burden with high casualty and perpetual disability rates. The general anticipation relies upon the volume of the underlying bleed, and level of postponed cerebral ischemia (DCI). The neurogenic pulmonary edema and cardiac manifestations indicate the severity of aneurysmal subarachnoid hemorrhage. Aneurysmal subarachnoid hemorrhage is frequently an irresistible event. Around 10% of patients with aneurysmal SAH pass on preceding achieving the clinic, 25% of patients die inside 24 hours of SAH onset, and around 45 % pass on inside 30 days; only 33% of patients will have a decent result after treatment.

Aneurysmal Subarachnoid Hemorrhage Market: Dynamics

Seasonal variations in the incidence of aneurysmal subarachnoid hemorrhage suggest a possible infective origin, however, current evidence are mixed. In the U.S., every year around 25000 to 30000 people (6– 11 for every 100000) encounter aneurysmal subarachnoid hemorrhage. Burst of cerebral aneurysms represents 50%-70% of these cases. Different causes incorporate bleeding from a cerebral tumor, drug abuse, anticoagulant treatment, ruptured arteriovenous deformities and hypertensive cerebral hemorrhage. Developing frequency of road accidents prompting head wounds and break of cerebral aneurysm cases, enhanced healthcare framework in developing nations; and development in awareness about SAH is driving the global market during the forecast period.

Aneurysmal Subarachnoid Hemorrhage Market: Segmentation

By treatment type, the aneurysmal subarachnoid hemorrhage market can be segmented into

  • By Diagnostic Test Type
  • Computed tomography (CT) scan
  • Magnetic resonance imaging (MRI)
  • Lumbar puncture
  • Xanthochromia
  • Cerebral angiography
  • Transcranial doppler ultrasound

By end-user, the aneurysmal subarachnoid hemorrhage market can be segmented into,

  • Hospitals
  • Clinics
  • ASC’s
  • Others

Growing awareness and technological assessments in upcoming medical devices and diagnostic imaging technologies are encouraging people to opt for modern treatment procedures to treat giant surgical and brain hemorrhage procedures. This is anticipated to boost the growth of aneurysmal subarachnoid hemorrhage market.

Aneurysmal Subarachnoid Hemorrhage Market: Region-wise Outlook

Regionally, the market is segmented into North America, Europe, Asia-Pacific, Latin America and the Middle East and Africa. The most critical reason for SAH (aneurysmal subarachnoid hemorrhage) is trauma or injury. Some different reasons for this condition are severe headache, intra-cerebral hemorrhage, cerebral venous sinus thrombosis and meningitis. Likewise, various lifestyle factors including smoking, hereditary disorders, hypertension, and extreme liquor utilization are additionally critical components for driving the global aneurysmal subarachnoid hemorrhage market during the forecast period. The most critical reason for SAH is trauma or injury. Some different reasons for this condition are severe headache, intra-cerebral hemorrhage, cerebral venous sinus thrombosis and meningitis. Likewise, various lifestyle factors including smoking, hereditary disorders, hypertension, and extreme liquor utilization are additionally critical components for driving the global aneurysmal subarachnoid hemorrhage market during the forecast period.

Aneurysmal Subarachnoid Hemorrhage Market: Key Players

Edge Therapeutics, Inc., Actelion Pharmaceuticals Ltd., Arbor Pharmaceuticals Inc., Mayfield Brain & Spine, Europa Group, GE Healthcare, Koninklijke Philips N.V., Siemens AG, Trivitron Healthcare, and Toshiba Medical Systems Corporation. Patients must be instructed about the risk of complications and symptomatic bleeding or brain hemorrhage. Patients should immediately consult a physician if they experience symptoms of stokes, migraine, or severe pain because of the possibility of impending trauma or bleeding.

MRR.BIZ has been compiled in-depth market research data in the report after exhaustive primary and secondary research. Our team of able, experienced in-house analysts has collated the information through personal interviews and study of industry databases, journals, and reputable paid sources.

The report provides the following information:

  • Tailwinds and headwinds molding the market’s trajectory
  • Market segments based on products, technology, and applications
  • Prospects of each segment
  • Overall current and possible future size of the market
  • Growth pace of the market
  • Competitive landscape and key players’ strategies

The main aim of the report is to:

  • Enable key stakeholder’s in the market bet right on it
  • Understand the opportunities and pitfalls awaiting them
  • Assess the overall growth scope in the near term
  • Strategize effectively with respect to production and distribution

MRR.BIZ is a leading provider of strategic market research. Our vast repository consists research reports, data books, company profiles, and regional market data sheets. We regularly update the data and analysis of a wide-ranging products and services around the world. As readers, you will have access to the latest information on almost 300 industries and their sub-segments. Both large Fortune 500 companies and SMEs have found those useful. This is because we customize our offerings keeping in mind the specific requirements of our clients.